dc.contributor.author | Pectasides, Dimitrios | en |
dc.contributor.author | Mylonakis, Alexander | en |
dc.contributor.author | Varthalitis, John | en |
dc.contributor.author | Kostopoulou, Mary | en |
dc.contributor.author | Constantinou, Andreas I. | en |
dc.contributor.author | Papazachariou, Kathrin | en |
dc.contributor.author | Antoniou, Fotini | en |
dc.contributor.author | Dimitriadis, Michael | en |
dc.contributor.author | Athanassiou, Athanassios E. | en |
dc.creator | Pectasides, Dimitrios | en |
dc.creator | Mylonakis, Alexander | en |
dc.creator | Varthalitis, John | en |
dc.creator | Kostopoulou, Mary | en |
dc.creator | Constantinou, Andreas I. | en |
dc.creator | Papazachariou, Kathrin | en |
dc.creator | Antoniou, Fotini | en |
dc.creator | Dimitriadis, Michael | en |
dc.creator | Athanassiou, Athanassios E. | en |
dc.date.accessioned | 2019-11-04T12:52:28Z | |
dc.date.available | 2019-11-04T12:52:28Z | |
dc.date.issued | 1997 | |
dc.identifier.uri | http://gnosis.library.ucy.ac.cy/handle/7/53297 | |
dc.description.abstract | This study was conducted to evaluate the efficacy of two different doses of ondansetron (8 mg vs. 24 mg) plus dexamethasone in the prevention of cisplatin (CDDP)-induced emesis and nausea (acute and delayed). The persistence of the anti-emetic efficacy during the second cycle of chemotherapy was also assessed. Eighty patients receiving high-dose CDDP (> 80 mg/m2) were randomized to have either ondansetron 8 mg plus dexamethasone 20 mg (8 mg group) or ondansetron 24 mg plus dexamethasone 20 mg (24 mg group), given intravenously as a single dose before the CDDP infusion. From days 2-5, all patients received oral ondansetron 8 mg twice daily. Seventy-five patients (38 in the 8 mg group and 37 in the 24 mg group) were evaluable for analysis. Among these, there were 24 patients who received ifosfamide (IFO) on the 2nd day of treatment | en |
dc.description.abstract | these patients were evaluated separately for delayed emesis. Complete protection from acute emesis was obtained in 26 (68.4%) and 26 (70.3%) patients, in the two groups, respectively. Complete protection against acute nausea was achieved in 23 (60.5%) and 24 (64.9%) patients, respectively. With respect to the delayed emesis, complete protection was achieved in 14 (56%) and 13 (50%) patients not receiving IFO and in 4 (30.8%) and 3 (27.3%) of those receiving IFO. The figures for the delayed nausea were: 12 (48%) and 13 (50%), 2 (15.4%) and 2 (18.2%), respectively. Similar protection against emesis and nausea was recorded during the second cycle of chemotherapy. Both regimens have the same efficacy and thus, taking into account the cost-effectiveness, 8 mg of ondansetron plus dexamethasone in a single intravenous dose should be used for the prevention of high-dose CDDP-induced emesis. © 1996 S. Karger AG, Basel. | en |
dc.source | Oncology (Switzerland) | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031060234&doi=10.1159%2f000227651&partnerID=40&md5=1f594dfc53e4ee04ce74c5923a2ee644 | |
dc.subject | article | en |
dc.subject | Antineoplastic Agents | en |
dc.subject | cancer chemotherapy | en |
dc.subject | human | en |
dc.subject | Humans | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | controlled study | en |
dc.subject | female | en |
dc.subject | major clinical study | en |
dc.subject | Middle Aged | en |
dc.subject | priority journal | en |
dc.subject | antiemetic agent | en |
dc.subject | Cisplatin | en |
dc.subject | clinical trial | en |
dc.subject | controlled clinical trial | en |
dc.subject | drug efficacy | en |
dc.subject | Prospective Studies | en |
dc.subject | Treatment Outcome | en |
dc.subject | dexamethasone | en |
dc.subject | randomized controlled trial | en |
dc.subject | male | en |
dc.subject | intravenous drug administration | en |
dc.subject | ifosfamide | en |
dc.subject | Acute Disease | en |
dc.subject | Antiemetics | en |
dc.subject | Ondansetron | en |
dc.subject | Nausea | en |
dc.subject | cost effectiveness analysis | en |
dc.subject | Antiemetic protection | en |
dc.subject | Drug Therapy, Combination | en |
dc.subject | Vomiting | en |
dc.title | Comparison of Two Different Doses of Ondansetron plus Dexamethasone in the Prophylaxis of Cisplatin-lnduced Emesis | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1159/000227651 | |
dc.description.volume | 54 | |
dc.description.startingpage | 1 | |
dc.description.endingpage | 6 | |
dc.author.faculty | Σχολή Θετικών και Εφαρμοσμένων Επιστημών / Faculty of Pure and Applied Sciences | |
dc.author.department | Τμήμα Βιολογικών Επιστημών / Department of Biological Sciences | |
dc.type.uhtype | Article | en |
dc.description.notes | <p>Cited By :13</p> | en |
dc.source.abbreviation | Oncology | en |
dc.contributor.orcid | Constantinou, Andreas I. [0000-0003-0365-1821] | |
dc.gnosis.orcid | 0000-0003-0365-1821 | |